{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:16:32Z","timestamp":1759709792508,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.burns.2019.10.028","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T18:25:39Z","timestamp":1576261539000},"page":"244-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy for toxic epidermal necrolysis: It is time for anti-TNFa biologics comparison"],"prefix":"10.1016","volume":"46","author":[{"given":"Georgios","family":"Gaitanis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis D.","family":"Bassukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"August","key":"10.1016\/j.burns.2019.10.028_bib0005","article-title":"Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","author":"Pham","year":"2019","journal-title":"Burns"},{"issue":"2","key":"10.1016\/j.burns.2019.10.028_bib0010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000338202","article-title":"Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin","volume":"224","author":"Gaitanis","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.burns.2019.10.028_bib0015","article-title":"Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient","volume":"2012","author":"Patmanidis","year":"2012","journal-title":"Case Rep Dermatol Med"},{"issue":"January","key":"10.1016\/j.burns.2019.10.028_bib0020","first-page":"1","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review","author":"Zhang","year":"2019","journal-title":"J Dermatol Treat"},{"issue":"October (10)","key":"10.1016\/j.burns.2019.10.028_bib0025","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/jdv.13725","article-title":"European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","volume":"30","author":"Enk","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.burns.2019.10.028_bib0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000284592","article-title":"Functionally active macrophage-derived myeloperoxidase in the skin of drug-induced toxic epidermal necrolysis","volume":"220","author":"Paquet","year":"2010","journal-title":"Dermatology"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417919307016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417919307016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T08:12:41Z","timestamp":1759651961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417919307016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0305417919307016"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2019.10.028","relation":{},"ISSN":["0305-4179"],"issn-type":[{"type":"print","value":"0305-4179"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy for toxic epidermal necrolysis: It is time for anti-TNFa biologics comparison","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2019.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd and ISBI. All rights reserved.","name":"copyright","label":"Copyright"}]}}